1-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-3-(4-chloro-phenyl)-urea

ID: ALA87277

Chembl Id: CHEMBL87277

Cas Number: 432042-02-9

PubChem CID: 446816

Max Phase: Preclinical

Molecular Formula: C15H19ClN4O

Molecular Weight: 306.80

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  Cn1nc(C(C)(C)C)cc1NC(=O)Nc1ccc(Cl)cc1

Standard InChI:  InChI=1S/C15H19ClN4O/c1-15(2,3)12-9-13(20(4)19-12)18-14(21)17-11-7-5-10(16)6-8-11/h5-9H,1-4H3,(H2,17,18,21)

Standard InChI Key:  FWIJKWMXNHRSRO-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA87277

   1-(5-Tert-butyl-2-methyl-2H-pyrazol-3-YL)-3-(4-chloro-phenyl)-urea

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 306.80

Molecular Weight (Monoisotopic): 306.1247

AlogP: 4.02

#Rotatable Bonds: 2

Polar Surface Area: 58.95

Molecular Species: NEUTRAL

HBA: 3

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 5

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 11.51

CX Basic pKa: 2.48

CX LogP: 4.17

CX LogD: 4.17

Aromatic Rings: 2

Heavy Atoms: 21

QED Weighted: 0.88

Np Likeness Score: -2.23

References

1. Tominaga Y, Jorgensen WL..  (2004)  General model for estimation of the inhibition of protein kinases using Monte Carlo simulations.,  47  (10): [PMID:15115396] [10.1021/jm0304358]

2. Regan J, Breitfelder S, Cirillo P, Gilmore T, Graham AG, Hickey E, Klaus B, Madwed J, Moriak M, Moss N, Pargellis C, Pav S, Proto A, Swinamer A, Tong L, Torcellini C..  (2002)  Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.,  45  (14): [PMID:12086485] [10.1021/jm020057r]

3. Regan J, Pargellis CA, Cirillo PF, Gilmore T, Hickey ER, Peet GW, Proto A, Swinamer A, Moss N..  (2003)  The kinetics of binding to p38MAP kinase by analogues of BIRB 796.,  13  (18): [PMID:12941343] [10.1016/s0960-894x(03)00656-5]

4. Kroe RR, Regan J, Proto A, Peet GW, Roy T, Landro LD, Fuschetto NG, Pargellis CA, Ingraham RH..  (2003)  Thermal denaturation: a method to rank slow binding, high-affinity P38alpha MAP kinase inhibitors.,  46  (22): [PMID:14561086] [10.1021/jm030120s]

5. Klüter S, Grütter C, Naqvi T, Rabiller M, Simard JR, Pawar V, Getlik M, Rauh D..  (2010)  Displacement assay for the detection of stabilizers of inactive kinase conformations.,  53  (1): [PMID:19928858] [10.1021/jm901297e]

6. Liu Y, Gray NS..  (2006)  Rational design of inhibitors that bind to inactive kinase conformations.,  2  (7): [PMID:16783341] [10.1038/nchembio799]

7. PubChem BioAssay data set, 

8. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds,  [10.6019/CHEMBL3301361]

9. Young RJ, Leeson PD..  (2018)  Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations.,  61  (15): [PMID:29620890] [10.1021/acs.jmedchem.8b00180]

10.  (2016)  7  (7): [10.1039/C6MD00262E]

Source

Source(3):

• Scientific Literature
• PubChem BioAssays
• AstraZeneca Deposited Data